Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Two-Cohort, Randomised, Placebo-controlled, Double-blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients With Chronic Heart Failure

NCT06299826 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06299826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06299826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Two-Cohort, Randomised, Placebo-controlled, Double-blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients With Chronic Heart Failure
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
June 4, 2024
Completion date
February 10, 2026
Enrollment
375 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure